TORONTO, ONTARIO, July 06, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that the Company has further adjourned its annual general and special meeting of shareholders (the "Meeting"). The Meeting was originally held on June 21, 2022, and was reconvened and further adjourned today prior to shareholders voting on the proposed consolidation of the Company’s common shares (the "Share Consolidation").
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.